NcXHF

MOLECULAR GENETIC PROFILING IN PEDIATRIC ONCOLOGY
ALL): Children’s Oncology Group (COG) Trial AALL0622. Paper presented
at: American Society of Hematology ASH Annual Meeting and
Exposition; December 2012; Atlanta, GA.
26. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating
lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371:
1005-1015.
27. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating
kinase and cytokine receptor signaling in high-risk acute lymphoblastic
leukemia. Cancer Cell. 2012;22:153-166.
28. Suryani S, Bracken LS, Harvey RC, et al. Evaluation of the in vitro and in
vivo effıcacy of the JAK inhibitor AZD1480 against JAK-mutated acute
lymphoblastic leukemia. Mol Cancer Ther. 2015;14:364-374.
29. Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor
therapy induces remission in a patient with refractory EBF1-PDGFRBpositive
acute lymphoblastic leukemia. J Clin Oncol. 2013;31:e413-e416.
30. Lengline E, Beldjord K, Dombret H, et al. Successful tyrosine kinase inhibitor
therapy in a refractory B-cell precursor acute lymphoblastic leukemia
with EBF1-PDGFRB fusion. Haematologica. 2013;98:e146-e148.
31. McGranahan N, Swanton C. Biological and therapeutic impact of intratumor
heterogeneity in cancer evolution. Cancer Cell. 2015;27:15-26.
32. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal
architecture and propagating cells in leukaemia. Nature. 2011;469:356-
361.
33. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal
origins of relapsed acute lymphoblastic leukemia. Science. 2008;322:
1377-1380.
34. Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent
in relapsed childhood acute lymphoblastic leukemia and confer
sensitivity to MEK inhibition. Blood. 2014;124:3420-3430.
35. Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory
standards for next-generation sequencing. Genet Med. 2013;15:733-747.
36. Majewski J, Schwartzentruber J, Lalonde E, et al. What can exome sequencing
do for you? J Med Genet. 2011;48:580-589.
37. Scollon S, Bergstrom K, Kerstein RA, et al. Obtaining informed consent
for clinical tumor and germline exome sequencing of newly diagnosed
childhood cancer patients. Genome Med. 2014;6:69.
38. Parsons DW, Angshumoy R, Monzon FA, et al. What’s in an exome?
Diversity of diagnostic and incidental fındings revealed by clinical tumor
and germline sequencing of 100 children with solid tumors. J Clin
Oncol. 2014;32:5s (suppl; abstr 10012).
39. Janeway KA, DuBois SG, Bender JLG, et al. Multicenter study assessing
tumor molecular profıles in advanced pediatric solid tumors. J Clin Oncol.
2014;32:5s (suppl; abstr 10011).
40. Hawryluk M, Wang K, Chmielecki J, et al. Clinical application of
comprehensive next-generation sequencing-based genomic profıling
for identifıcation of actionable genomic alterations in pediatric
solid tumors and hematolymphoid malignancies: The Foundation
Medicine pediatric experience. J Clin Oncol. 2014;32:5s (suppl; abstr
10035).
41. Walsh M WG, Edmonson M, et al. Incidence of germline mutations in
cancer-predisposition genes in children with hematologic malignancies:
a report from the Pediatric Cancer Genome Project. Paper presented
at: American Society of Hematology Annual Meeting and
Exposition; December 2014; San Francisco, CA.
42. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting
of incidental fındings in clinical exome and genome sequencing.
Genet Med. 2013;15:565-574.
43. Fojo T, Giannakakou P. Decade in review-funding in cancer research:
National Cancer Institute awards-a work in progress. Nat Rev Clin Oncol.
2014;11:634-636.
44. Abrams J, Conley B, Mooney M, et al. National Cancer Institute’s Precision
Medicine Initiatives for the new National Clinical Trials Network.
Am Soc Clin Oncol Educ Book. 2014:71-76.
45. Bhatla T, Jones CL, Meyer JA, et al. The biology of relapsed acute lymphoblastic
leukemia: opportunities for therapeutic interventions. J Pediatr
Hematol Oncol. 2014;36:413-418.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e607